Fig. 3. Enhanced antitumor activities against primary tumors.
a–c C57BL/6 mice were subcutaneously inoculated with 5 × 105 luciferase-expressing B16-F10 (B16-F10-Luc) cells. When tumor sizes reached ~100 mm3 (counted as day 0), the mice were intratumorally injected with 50 μL of VV-RFP, VV-GM, or VV-iPDL1/GM (5 × 107 pfu per tumor) or PBS at days 0, 3, and 7. Bioluminescence monitoring a, b and caliper measurement c of B16-F10-Luc cells were performed on the indicated days. Data are presented as the means ± SD (n = 5 mice). Significant differences are indicated as *P < 0.05 determined by two-tailed Student’s t-test. d, e Py230 d or MC38 e tumor volume was monitored by caliper measurement using the same treatment schedule as in a–c. Data are presented as the means ± SD (n = 5 mice).